Immuron nets 136% increase in global sales this year compared to financial year 2022

Globally integrated biopharmaceuticals company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has had a bumper year for its over-the-counter gastrointestinal and...

Related Keywords

United States ,Australia ,Australian , ,Immuron Ltd ,Passport Health Travel Clinics ,Australian Bureau Of Statistics ,Therapeutic Goods Administration ,Australian Bureau ,